ESMO 2023: Recommendations From Prof. Lillie Shockney for Metastatic Breast Cancer
Friday, October 20, 2023
16:00–17:20 CEST; Proffered Paper Session
Supportive and Palliative Care
2030O Remote symptom monitoring with electronic patient-reported outcomes (ePROs) during treatment for metastatic cancer: Results from the PRO-TECT trial (Alliance AFT-39). E Basch
Saturday, October 21, 2023
10:15–11:35 CEST; Proffered Paper Session
Breast Cancer, Metastatic
376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase 3 DESTINY-Breast04 study. S Modi
378O Persistence under abemaciclib and endocrine treatment (ABA+ET) in patients with advanced breast cancer (aBC) – first results of the randomized IMPACT Trial comparing patient coaching with the MASCC Oral Agent Teaching Tool (MOATT) versus local routine patient coaching (LC). MK Welslau
Sunday, October 22, 2023
8:30–9:55 CEST; Mini Oral Session
Breast Cancer, Metastatic
379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study. P Schmid
380MO SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): results from a phase I/II, single-arm, basket trial. Y Yin
382MO Updated results from the phase 1/2 study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD ) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer. NU Lin
384MO Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-naïve, hormone receptor-positive (HR+) advanced breast cancer (FALCON). J Robertson
387MO First Results of the SOLTI-1903 HOPE's Patient-Centric Molecular Screening Program in Advanced Breast Cancer. T Pascual
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
Disclosure statements are available on the authors' profiles: